ECC 2015: CheckMate 025 trial showed nivolumab improved overall survival in advanced kidney cancer - European Medical Journal

ECC 2015: CheckMate 025 trial showed nivolumab improved overall survival in advanced kidney cancer

Oncology

CheckMate 025, a phase 3 clinical trial, compared the anti-programmed cell death protein-1 (PD-1) antibody, nivolumab, with the standard treatment, everolimus, in patients with clear cell renal cell carcinoma. CheckMate 025 is the first clinical trial to show an improvement in overall survival in these patients for any immune checkpoint inhibitor agent. The survival benefit was seen in patients regardless of the extent of the PD-1 ligand expression in their tumours.

Presented at the European Cancer Conference (ECC) 2015 by Padmanee Sharma, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>